Most New Drugs Are Still Too Costly at Launch, ICER Says

Most new drugs are still too costly at launch, ICER says

A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.  

Launch prices for new medicines dipped slightly last year but remain high, analysis finds

The median net price for 202 newly launched drugs, when adjusted for inflation and manufacturer discounts, rose by 35% last year from 2022

Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025

The median annual net launch price for new prescription drugs increased 35% from 2022 to 2025, to $257,000, according to a report released by the Institute for Clinical and Economic Review and West Health. Nearly 25% of drugs in 2025 launched above $500,000 and 34% launched between $200,000 and $500,000. The groups found that even if drug characteristics impacting launch prices remain constant, such as product type, therapeutic class, and orphan…

New ICER report suggests drug launch prices are outpacing their worth

The median list price of drugs at launch rose 24% from 2022 to 2025, and the net prices of those drugs rose even higher, according to a new report from the Institute for Clinical and ...